|
MechanismSARS-CoV-2 S protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date21 May 2021 |
100 Clinical Results associated with Moderna Japan Co. Ltd.
0 Patents (Medical) associated with Moderna Japan Co. Ltd.
100 Deals associated with Moderna Japan Co. Ltd.
100 Translational Medicine associated with Moderna Japan Co. Ltd.